2023 World Conference on Lung Cancer (Posters)-EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan

EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the effectiveness and safety of lorlatinib, a third-generation tyrosine kinase inhibitor, for patients with previously treated ROS1-rearranged non-small cell lung cancer (NSCLC) in Taiwan. ROS1 rearrangement is a rare driver oncogene found in 1% of NSCLC cases. While crizotinib and entrectinib have shown efficacy as first-line treatments for ROS1-rearranged NSCLC, the role of lorlatinib in treating these patients remains unclear.<br /><br />The study included a total of 10 patients with ROS1-rearranged NSCLC who were treated with lorlatinib. Four patients received lorlatinib as a second-line treatment, and six patients received it as a third-line or subsequent treatment. The overall objective response rate (ORR) was 30%, and the intra-cranial ORR was 22%. During the 27-month follow-up period, four patients experienced disease progression, while six patients continued to receive lorlatinib treatment. The median progression-free survival was 24 months, and all patients were still alive at the end of the study.<br /><br />All patients experienced at least one treatment-related adverse event during lorlatinib therapy. The most common adverse event was hyperlipidemia, which occurred in 80% of patients (grade 1 or 2). One patient experienced grade 3 hyperlipidemia, one patient had grade 1 edema, two patients had weight gain (grade 1 or 2), and two patients had neurological impairment (grade 1 or 2). Only one patient had to stop lorlatinib treatment due to neurological impairment.<br /><br />In conclusion, this real-world study demonstrated the durable effectiveness of lorlatinib for previously treated NSCLC patients with ROS1 rearrangements. The safety profile of lorlatinib was consistent with previous findings. This study provides real-world evidence supporting the use of lorlatinib as a potential treatment option for patients with previously treated ROS1-rearranged NSCLC.

Asset Subtitle

Xuet Yit Chen

Meta Tag

Speaker Xuet Yit Chen

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

lorlatinib

tyrosine kinase inhibitor

ROS1-rearranged NSCLC

effectiveness

safety

Taiwan

crizotinib

entrectinib

progression-free survival

adverse events